Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > REGULATORY
REGULATORY
- MHLW Suggests Regulation for Research Likely to Be Used in Ads
July 25, 2014
- Cabinet Approves Health, Medical Strategy
July 24, 2014
- Toshihiko Takeda Appointed Councilor in Charge of Health Insurance
July 24, 2014
- PMDA Reviewing Infliximab for Risk of Rhabdomyolysis
July 24, 2014
- PAFSC’s First Committee to Discuss MSD’s Insomnia Drug on Aug. 1
July 24, 2014
- Ex-Novartis Employee Indicted on Additional Charges, Prosecutors to Wind Up Probe: Reports
July 23, 2014
- Chain Pharmacies’ Drug Price Settlement Rate in June Triples from 2 Years Ago
July 23, 2014
- MHLW FY2015 Budget Request to Center on PM Abe’s Growth Strategy
July 22, 2014
- ICH M7 Guideline Reaches Step 4; MHLW to Issue Notification
July 22, 2014
- Ministry Panel Agrees to Add Kitasato Daiichi Sankyo Vaccine’s Squarekids to Routine Vaccine Program
July 18, 2014
- Post-Shipment Quality Control Testing of Radiopharmaceuticals Would Not Violate GMP: MHLW
July 18, 2014
- Is Legal Regulation Necessary? Clinical Research at Turning Point 2: Prof. Kageyama of Jikei Univ.
July 18, 2014
- MOF Official in Charge of Health Spending to “Carefully” Discuss Budgets
July 17, 2014
- Council OKs Public-Knowledge Based Application for Oxaliplatin at Doses Approved Overseas
July 16, 2014
- 50% Price Rule, Unifying Price Brackets Starters of Next Generic Price Revision Discussions: Ministry Official
July 15, 2014
- MHLW Panel to Elaborate Proposed Scheme to Broaden Drug Development Requests
July 15, 2014
- Editor’s Pick: Five Healthcare News Headlines for June 30 - July 11
July 14, 2014
- Revised PAL to Go Live on November 25: Ministry Exec
July 14, 2014
- Science Ministry’s Updated Guidelines to Require Research Data Preservation
July 14, 2014
- Draft Policy on Resource Allocation Focuses Funding on 9 Fields of Healthcare R&D
July 14, 2014
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…